Texas Retina First in the US to Randomize a Patient in the i-SIGHT2 Bioelectric Therapy for Dry AMD Clinical Trial
The i-SIGHT2 pivotal clinical trial is evaluating the investigational i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration (AMD), and on July 1, 2026, Texas Retina’s Patrick D.
read more
Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more
Dr. Abbey Presented on Retinal Sustained Drug Delivery Research at Retina World Congress
At the recently held Retina World Congress 2026 meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented on the evolving clinical trial landscape for sustained drug delivery in retinal disease. Dr.
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
10 New Clinical Trials Available at Texas Retina
In the last two decades, medical researchers have made significant advances in the diagnosis and treatment of retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision.
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read more

